About Boundless Bio, Inc.
https://boundlessbio.comBoundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers.
CEO
Zachary Hornby
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
FMR LLC
Shares:3.1M
Value:$3.9M
BB BIOTECH AG
Shares:1.37M
Value:$1.73M
NEXTECH INVEST, LTD.
Shares:1.23M
Value:$1.55M
Summary
Showing Top 3 of 59
About Boundless Bio, Inc.
https://boundlessbio.comBoundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $14.84M ▼ | $-13.88M ▲ | 0% | $-0.62 ▲ | $-13.57M ▲ |
| Q2-2025 | $0 | $16.74M ▼ | $-15.68M ▲ | 0% | $-0.7 ▲ | $-15.36M ▲ |
| Q1-2025 | $0 | $17.34M ▼ | $-15.76M ▲ | 0% | $-0.71 ▲ | $-17.02M ▲ |
| Q4-2024 | $0 | $18.28M ▼ | $-16.45M ▲ | 0% | $-0.84 ▼ | $-17.98M ▲ |
| Q3-2024 | $0 | $18.71M | $-16.51M | 0% | $-0.74 | $-18.45M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $117.57M ▼ | $168.72M ▼ | $58.55M ▲ | $110.17M ▼ |
| Q2-2025 | $127.15M ▼ | $179.45M ▼ | $56.76M ▲ | $122.69M ▼ |
| Q1-2025 | $138.25M ▼ | $191.24M ▼ | $54.65M ▼ | $136.59M ▼ |
| Q4-2024 | $152.11M ▼ | $206.41M ▲ | $55.77M ▲ | $150.64M ▼ |
| Q3-2024 | $167.13M | $175.09M | $10.01M | $165.08M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-13.88M ▲ | $-10.2M ▲ | $10.48M ▼ | $0 ▼ | $283K ▲ | $-10.21M ▲ |
| Q2-2025 | $-15.68M ▲ | $-11.83M ▲ | $11.29M ▲ | $117K ▲ | $-420K ▲ | $-11.88M ▲ |
| Q1-2025 | $-15.76M ▲ | $-14.53M ▲ | $3.06M ▲ | $0 ▼ | $-11.47M ▲ | $-14.59M ▲ |
| Q4-2024 | $-16.45M ▲ | $-15.56M ▼ | $1.82M ▼ | $113K ▲ | $-13.63M ▼ | $-16.03M ▼ |
| Q3-2024 | $-16.51M | $-13.27M | $22.13M | $-13K | $8.85M | $-13.75M |
CEO
Zachary Hornby
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
FMR LLC
Shares:3.1M
Value:$3.9M
BB BIOTECH AG
Shares:1.37M
Value:$1.73M
NEXTECH INVEST, LTD.
Shares:1.23M
Value:$1.55M
Summary
Showing Top 3 of 59